🇺🇸 Victoza (liraglutide) in United States

FDA authorised Victoza (liraglutide) on 25 January 2010 · 1,585 US adverse-event reports

Marketing authorisation

FDA — authorised 25 January 2010

  • Application: NDA022341
  • Marketing authorisation holder: NOVO NORDISK INC
  • Local brand name: VICTOZA
  • Indication: SOLUTION — SUBCUTANEOUS
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 416 reports (26.25%)
  2. Blood Glucose Increased — 260 reports (16.4%)
  3. Diarrhoea — 165 reports (10.41%)
  4. Decreased Appetite — 145 reports (9.15%)
  5. Pancreatitis — 138 reports (8.71%)
  6. Vomiting — 129 reports (8.14%)
  7. Headache — 98 reports (6.18%)
  8. Injection Site Haematoma — 87 reports (5.49%)
  9. Blood Glucose Decreased — 74 reports (4.67%)
  10. Injection Site Pain — 73 reports (4.61%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Victoza (liraglutide) approved in United States?

Yes. FDA authorised it on 25 January 2010.

Who is the marketing authorisation holder for Victoza (liraglutide) in United States?

NOVO NORDISK INC holds the US marketing authorisation.